Review of triazolam data.
Klett
C J
CJ
D000367:Age Factors; D000368:Aged; D002986:Clinical Trials as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003866:Depressive Disorder / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D005479:Flurazepam / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008569:Memory Disorders / Q000139:chemically induced; D015337:Multicenter Studies as Topic; D010259:Paranoid Disorders / Q000139:chemically induced; D010919:Placebos; D017286:Polysomnography; D007319:Sleep Initiation and Maintenance Disorders / Q000175:diagnosis / Q000188:drug therapy*; D014229:Triazolam / Q000009:adverse effects / Q000627:therapeutic use*
D010919:Placebos; D014229:Triazolam; D005479:Flurazepam